Search

Displaying results 2211 - 2220 of 5898 in total
  1. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    falciparum malaria that is resistant to other antimalarials. … Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria.

    Synonyms: Lumefantrine co-artemether
  2. Drug

    Mefloquine

    go.drugbank.com/drugs/DB00358
    Approved

    The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. … risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to

  3. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease. … Furthermore, the pegylation of pegunigalsidase alfa promotes higher stability and a longer half-life, allowing it to reach target organs with a lower dose and frequency of administration.

  4. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [A243769] Conversely, tezepelumab, which targets the upstream master regulator TSLP, has the potential to be effective across asthma endotypes. … existing asthma treatments such as [omalizumab], [mepolizumab], [reslizumab], [benralizumab], and [dupilumab] act on specific downstream mediators of the inflammatory response, they are mostly limited to

  5. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients.

  6. Drug

    Pancrelipase lipase

    go.drugbank.com/drugs/DB13147
    ApprovedInvestigational

    Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase lipase is an enzyme secreted by the pan...

  7. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    The amino acid sequence of two compounds differ by seven amino acids [L1458]. … Apart from its FDA and EMA indication, ecallantide has been used off label in the management of nonhistaminergic angioedema, not due to HAE [A32017].

  8. Drug

    Ximelagatran

    go.drugbank.com/drugs/DB04898
    ApprovedWithdrawn

    In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries … Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.

  9. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers. … A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track

  10. Drug

    Mephenytoin

    go.drugbank.com/drugs/DB00532
    ApprovedWithdrawn

    Mephenytoin is known to target sodium channel protein type 5 subunit alpha. … Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures.